Research programme: metastatic melanoma therapeutics and diagnostics - SolaranRx

Drug Profile

Research programme: metastatic melanoma therapeutics and diagnostics - SolaranRx

Alternative Names: SRX-1177

Latest Information Update: 11 Jan 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator University of New Mexico
  • Class Peptides; Radiopharmaceutical diagnostics; Radiopharmaceuticals
  • Mechanism of Action Melanocortin type 1 receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Malignant melanoma

Most Recent Events

  • 07 Jan 2016 SolaranRx establishes CRADA with National Cancer Institute for the development of SRX 1177 in Malignant melanoma
  • 22 Apr 2015 SRX 1177 receives Orphan Drug status for Malignant melanoma in USA
  • 10 Sep 2014 Preclinical trials in Malignant melanoma in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top